Antibody-mediated depletion of CCR10+EphA3+ cells ameliorates fibrosis in IPF

抗体介导的 CCR10+EphA3+ 细胞清除可改善特发性肺纤维化中的纤维化。

阅读:5
作者:Miriam S Hohmann ,David M Habiel ,Milena S Espindola ,Guanling Huang ,Isabelle Jones ,Rohan Narayanan ,Ana Lucia Coelho ,Justin M Oldham ,Imre Noth ,Shwu-Fan Ma ,Adrianne Kurkciyan ,Jonathan L McQualter ,Gianni Carraro ,Barry Stripp ,Peter Chen ,Dianhua Jiang ,Paul W Noble ,William Parks ,John Woronicz ,Geoffrey Yarranton ,Lynne A Murray ,Cory M Hogaboam

Abstract

Idiopathic pulmonary fibrosis (IPF) is characterized by aberrant repair that diminishes lung function via mechanisms that remain poorly understood. CC chemokine receptor (CCR10) and its ligand CCL28 were both elevated in IPF compared with normal donors. CCR10 was highly expressed by various cells from IPF lungs, most notably stage-specific embryonic antigen-4-positive mesenchymal progenitor cells (MPCs). In vitro, CCL28 promoted the proliferation of CCR10+ MPCs while CRISPR/Cas9-mediated targeting of CCR10 resulted in the death of MPCs. Following the intravenous injection of various cells from IPF lungs into immunodeficient (NOD/SCID-γ, NSG) mice, human CCR10+ cells initiated and maintained fibrosis in NSG mice. Eph receptor A3 (EphA3) was among the highest expressed receptor tyrosine kinases detected on IPF CCR10+ cells. Ifabotuzumab-targeted killing of EphA3+ cells significantly reduced the numbers of CCR10+ cells and ameliorated pulmonary fibrosis in humanized NSG mice. Thus, human CCR10+ cells promote pulmonary fibrosis, and EphA3 mAb-directed elimination of these cells inhibits lung fibrosis.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。